Through inhibiting post-transcriptional factors of TRAF4, hsa-miR-21-3p promoted proliferation and anti-apoptosis, and hsa-miR-21-3p has potential to be a biomarker for the early diagnosis of ESCC. This evidence concerns the gene TRAF4 and esophageal squamous cell carcinoma.